Seroatlas · Human Serome Atlas

BCL2A1

Bcl-2-related protein A1

Also known as: ACC-1, ACC-2, ACC1, ACC2, B2LA1_HUMAN, BCL2L5, BFL1, GRS, HBPA1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q16548
Gene: BCL2A1
Ensembl: ENSG00000140379
Chromosome: 15
Canonical length: 175 aa
Protein class: Cancer-related genes, Predicted intracellular proteins

OverviewNCBI Gene

This gene encodes a member of the BCL-2 protein family. The proteins of this family form hetero- or homodimers and act as anti- and pro-apoptotic regulators that are involved in a wide variety of cellular activities such as embryonic development, homeostasis and tumorigenesis. The protein encoded by this gene is able to reduce the release of pro-apoptotic cytochrome c from mitochondria and block caspase activation. This gene is a direct transcription target of NF-kappa B in response to inflammatory mediators, and is up-regulated by different extracellular signals, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), CD40, phorbol ester and inflammatory cytokine TNF and IL-1, which suggests a cytoprotective function that is essential for lymphocyte activation as well as cell survival. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

175 residues, UniProt reviewed canonical sequence.

>Q16548|BCL2A1
     1  MTDCEFGYIY RLAQDYLQCV LQIPQPGSGP SKTSRVLQNV AFSVQKEVEK NLKSCLDNVN
    61  VVSVDTARTL FNQVMEKEFE DGIINWGRIV TIFAFEGILI KKLLRQQIAP DVDTYKEISY
   121  FVAEFIMNNT GEWIRQNGGW ENGFVKKFEP KSGWMTFLEV TGKICEMLSL LKQYC

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BCL2A1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.26
Highest tissue expression: 583 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 583 nTPM
appendix: 100 nTPM
lung: 93 nTPM
spleen: 86 nTPM
lymph node: 68 nTPM
tonsil: 54 nTPM

Single-cell type

neutrophils: 4,588 nCPM
monocytes: 1,075 nCPM
cdc: 280 nCPM
neutrophil progenitors: 258 nCPM
macrophages: 248 nCPM
endometrial secretory cells: 234 nCPM

Immune cell

neutrophil: 565 nTPM
non-classical monocyte: 384 nTPM
eosinophil: 294 nTPM
intermediate monocyte: 197 nTPM
memory B-cell: 67 nTPM
total PBMC: 50 nTPM

Brain region

cerebral cortex: 72 nTPM
pons: 20 nTPM
thalamus: 8.7 nTPM
white matter: 8.2 nTPM
medulla oblongata: 6 nTPM
choroid plexus: 5.2 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.91
gnomAD pLI: 0.21
gnomAD missense Z: 1.13
DepMap mean gene effect: -0.02
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

channel activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of BCL2A1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BCL2A1 as an antibody target. Whether an autoantibody or antibody against BCL2A1 could matter depends on whether native BCL2A1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BCL2A1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label BCL2A1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...